Table 3 Main COVID-19 positive patients’ characteristics
Sex | |
Male 11 (84.6%) | |
Female 2 (15.4%) | |
Age | |
Median 69.7 years (range 59.7–84.9) | |
Mean 69.8 years | |
ECOG Performance Status | |
PS0 3 (23.1%) | |
PS1 8 (61.5%) | |
PS2 0 (0%) | |
PS3 2 (15.4%) | |
Smoking habit | |
Smoker 9 (69.2%) | |
Former smoker (15.4%) | |
Non smoker (15.4%) | |
Comorbidities | |
Arterial hypertension 4 (30.7%) | |
Other cardiovascular diseases 6 (46.2%) | |
Arrhytmias 2 (15.4%) | |
Diabetes 2 (15.4%) | |
Infectious diseases 2 (15.4%) | |
Gastrointestinal diseases 2 (15.4%) | |
Number of comorbidities | |
None 1 (7.7%) | |
One 4 (30.8%) | |
Two 3 23.1% | |
Three or more 5 (38.5%) | |
Tumor diagnosis | |
NSCLC 8 (61.5%) | |
Head and neck SCC 2 (15.4%) | |
Multiple myeloma 1 (7.7%) | |
Breast cancer 1 (7.7%) | |
Rectal cancer 1 (7.7%) | |
Tumor stage | |
Stage IV 4 (30.8%) | |
Stage III 7 (53.8%) | |
Stage II 1 (7.7%) | |
Unknown 1 (7.7%) | |
Ongoing treatment | |
Radical or adjuvant/neoadjuvant radiotherapy 6 (46.2%) | |
Palliative radiotherapy 4 (30.8%) | |
Chemotherapy 4 (30.8%) | |
Immunotherapy 2 (15.4%) | |
Treatment suspension | |
No 6 (46.2%) | |
Temporary 1 (7.7%) | |
Definitive 6 (46.2%) | |
Chest radiograph | |
Positive 11 (84.6%) | |
Negative 2 (15.4%) | |
Chest CT scan | |
Positive 6 (46.2%) | |
Negative 0 | |
Not performed 7 (46.2%) | |
COVID-19 treatment | |
Hydroxychloroquine 11 (84.6%) | |
Lopinavir/ritonavir 8 (61.5%) | |
Other antivirals 3 (23.1%) | |
Tocilizumab 3 (23.1%) | |
Azitromicin 9 (69.2%) | |
No treatment 2 (15.4%) | |
Respiratory support | |
Supplemental oxygen 10 (76.9%) | |
Non-invasive ventilation 1 (7.7%) | |
Invasive ventilation 0 | |
COVID-19 outcome | |
Negativized 6 (46.2%) | |
Alive positive 2 (15.4%) | |
Deceased 5 (38.5%) |